Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Research Article

Increased Serum Levels of CD95 in Alzheimer’s Disease

Richartz E.a · Noda S.a · Schott K.a · Günthner A.a · Lewczuk P.b · Bartels M.a

Author affiliations

aDepartment of Psychiatry and Psychotherapy, University of Tübingen, and bNeurochemistry Laboratory, University of Göttingen, Germany

Related Articles for ""

Dement Geriatr Cogn Disord 2002;13:178–182

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Published online: March 13, 2002
Issue release date: March 2002

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Abstract

There is growing evidence for a role of apoptosis in Alzheimer’s disease (AD). Recent findings suggest an increased susceptibility of lymphocytes to apoptosis in AD. To prove the hypothesis of systemic alterations in the apoptotic balance in AD, serum and cerebrospinal fluid levels of soluble CD95, which is known to mediate apoptosis, were measured. In the serum, AD patients exhibited significantly higher levels of CD95 than the controls (p = 0.017), suggesting an involvement of peripheral markers in AD.

© 2002 S. Karger AG, Basel


References

  1. Stadelmann C, Bruck W, Bancher C, Jellinger K, Lassmann H: Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol 1998;57:456–464.
    External Resources
  2. Su JH, Anderson AJ, Cummings BJ, Cotman CW: Immunohistological evidence for apoptosis in Alzheimer’s disease. Neuroreport 1994;5:2529–2533.
  3. Lassmann H, Bancher C, Breitschopf CJ, Wegiel J, Bobinski M, Jellinger K, Wisniewski HM: Cell death in Alzheimer’s disease evaluated by DNA fragmentation in situ. Acta Neuropathol (Berl) 1995;89:35–41.
  4. Dragunow M, Faull RJM, Lawlor P, Beilharz EJ, Singleton K, Walker EB, Mee E: In situ evidence for DNA fragmentation in Huntington’s disease striatum and Alzheimer’s disease temporal lobes. Neuroreport 1995;6:1053–1057.
  5. Smale G, Nichols NR, Grady DR, Fich CE, Horton WE: Evidence for apoptotic cell death in Alzheimer’s disease. Exp Neurol 1995;133:225–230.
  6. Cotman CW: Apoptosis decision cascades and neuronal degeneration in Alzheimer’s disease. Neurobiol Aging 1998;19:29–32.
  7. Jellinger KA: Cell death mechanism in Parkinson’s disease. J Neural Transm 2000;107:1–29.
    External Resources
  8. De la Monte SM, Sohn YK, Wand JR: Correlates of p53 and Fas (CD 95)-mediated apoptosis in Alzheimer’s disease. J Neurol Sci 1997;152:73–83.
    External Resources
  9. Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney MJ: Direct evidence of oxidative injury produced by the Alzheimer’s β-amyloid peptide (1–40) in cultured hippocampal neurons. Exp Neurol 1995;131:193–202.
  10. LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G: The Alzheimer’s Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 1995;9:21–30.
  11. Mattson MP, Pedersen WA: Presenilins, the endoplasmic reticulum, and neuronal apoptosis in AD. J Neurochem 1998;70:1–14.
    External Resources
  12. Ivins KJ, Thornton PL, Rohn TT, Cotman CW: Neuronal apoptosis induced by β-amyloid is mediated by caspase-8. Neurobiol Dis 1999;6:440–449.
    External Resources
  13. Nagata S, Goldstein P: The Fas death factor. Science 1995;267:1449–1456.
  14. Ciusani E, Frigerio S, Gelati M, Corsini E: Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 1998;82:5–12.
    External Resources
  15. Tarkowski E, Rosengren L, Blomstrand C, Jensen C, Ekholm S, Tarkowski A: Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke 1999;30:321–327.
  16. Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, Riederer P, Nagatsu T: The soluble form of fas-molecule is elevated in parkinsonian brain tissues. Neurosci Lett 1996;220:195–198.
  17. Owen AD, Schapira AHV, Jenner P, Marsden CD: Indices of oxidative stress in Parkinson’s disease, Alzheimer’s disease and dementia with Lewy bodies. J Neural Transm 1997;51(suppl):167–173.
  18. Nishimura T, Akiyama H, Yonehara S, Kondo H, Ikeda K, Kato M, Iseki E, Kosaka K: Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res 1995;695:137–145.
  19. De la Monte SM, Sohn YK, Ganju N, Wands JR: p53- and CD95-associated apoptosis in neurodegenerative disorders. Lab Invest 1998;78:401–411.
  20. Cheng JT, Zhou T, Liu C, Shapiro JC, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759–1762.
  21. Mysler E, Bini P, Drappa A, Ramos P, Friedman SM, Krammer PH, Elkon KB: The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994;93:1029–1034.
  22. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH: Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 1995;6:1562–1569.
  23. Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku M, Azuma M, Yagita H, Okumura K, Koike T: Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. J Exp Immunol 1997;107:89–95.
  24. Hasunuma T, Kayagaki N, Asahara H, Motokawa S, Kobata T, Yagita H, Aoho H, Sumida T, Okumura K, Nishioka K: Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 1997;40:30–36.
  25. Hiromatsu Y, Bednarczuk T, Soyejima E, Miyake I, Yang D, Fukazewa H, Nonaka K: Increased serum levels of sFas in patients with Graves disease. Thyreoid 1999;9:341–345.
  26. Lynch DH, Ramsdell F, Alderson MR: Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995;16:569–574.
  27. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, Müller C, Tschopp J: Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133:335–343.
  28. Becher B, Barker PA, Owens T, Antel JP: CD95-CD95L: Can the brain learn from the immune system? Trends Neurosci 1998;21:114–117.
  29. Torre D, Zeroli C, Speranza F, Martehani R, Fiori G, Airoldi M: Serum levels of Fas/Apo1 and bcl-2 in children with HIV-1 infection. Scand J Infect Dis 1998;30:565–568.
  30. Hori Y, Wada H, Mori Y, Shimura M, Hiyoyama K, Nakasaki T, Nishii K, Tamaki S, Mishikawa M, Deguchi K, Minami N, Shiku H: Plasma sFas and sFas ligand levels in patients with thrombocytopenic purpura and in those with disseminated intravascular coagulation. Am J Hematol 1999;61:21–25.
  31. Siegel RM, Fleisher TA: The role of fas and related death receptors in autoimmune and other disease states. J Allergy Clin Immunol 1999;103:729–738.
  32. Kawakami H, Shigematsu Y, Ohtsuka T, Okayama H, Hayashi Y, Hara Y, Kodoma K, Hamada M, Hiwada K: Increased sFas in patients with dilatative cardiomyopathy. Jpn Circ J 1998;62:873–876.
  33. Eckert A, Cotman CW, Zerfass R, Hennerici M, Müller WE: Lymphocytes as cell model to study apoptosis in Alzheimer’s disease: Vulnerability to programmed cell death appears to be altered. J Neural Transm 1998;54(suppl):259–267.
  34. Maesaka JK, Palaia T, Chowdhury SA, Shimamura T, Fischbane S, Reichman W, Coyne A, O’Rear JJ, El-Sabban ME: Partial characterization of apoptotic factor in Alzheimer plasma. Am J Physiol 1999;276:F521–F527.
    External Resources
  35. Singh VK, Guthikonda P: Circulating cytokines in Alzheimer’s disease. J Psychiatr Res 1997;31:657–660.
  36. Sulger J, Dumais-Huber C, Zerfass R, Henn FA, Aldenhoff JB: The calcium response of human T lymphocytes is decreased in aging but increased in Alzheimer’s dementia. Biol Psychiatry 1999;45:737–742.
  37. McKhann G, Drachmann D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  38. Folstein MF, Folstein SE, McHugh PR: ‘Mini-Mental-State’: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1974;12:189–198.
  39. Richartz E, Noda S, Wormstall H, Schott K: Alterations of cytokine levels in Alzheimer’s disease. Exp Clin Endocrinol Diabetes 1999;107:A32–A33.
  40. Lombardi VRM, Garcia M, Rey L, Cacabelos R: Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease individuals. J Neuroimmunol 1999;97:163–171.
    External Resources
  41. Trifilieff A, Futjitani Y, Coyle AJ, Bertrand C: Fas-induced death of a murine pulmonary epithelia cell line: Modulation by proinflammatory cytokines. Fundam Clin Pharmacol 1999;13:656–661.
  42. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, Mohs R, Pasinetti GM: Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000;57:1153–1160.
  43. Terry RD: Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 2000;59:1118–1119.
    External Resources
  44. Licastro F, Masliah E, Pedrini S, Thal LJ: Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer’s disease. Effects of gender and apolipoprotein E genotype. Dement Geriatr Cogn Disord 2000;11:25–28.

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Published online: March 13, 2002
Issue release date: March 2002

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.